As a research-led healthcare company, we strive to develop solutions and medicines where there is high unmet need.
Wintermute launched the Doxall™ Sanitiser range in 2021 and has multiple other therapeutic formulations in its development pipeline. These including a Covid 19 preventative and treatment inhalant and a topical shingles therapeutic. Wintermute formulations demonstrate exceptional potential for the treatment of infections. Some key advantages of include:
High levels of potency in eradication infectious organisms.
High levels of safety captured during in-vitro and in-vivo testing.
Activity against gram-positive and gram-negative bacteria, fungi and viruses.
Zero evidence of resistance development during standardized testing (undecylenic acid formulation)
Ongoing protection against infections.
No harmful chemicals, water-based, sustainable naturally occurring active ingredients.
Wintermute compounds have demonstrated efficacy for a wide range of organisms; most of which make up the CDC’s Biggest Threats list
At Wintermute Biomedical, we are performing leading-edge research and development into the discovery of next-generation therapeutics and consumer products to prevent and combat infectious diseases. We are actively researching, developing and testing:
Antibacterials, anti-virals and anti-fungals.
Systemic therapeutics, including for the treatment of respiratory disease and blood stream infections.
Sanitiser agents and coatings for use in numerous industry segments. Long acting antimcrobial and surfactant with unparalleled safe profile. Doxall™ launched 2021
Our team won’t rest until our patented science is delivering better, safer and greener solutions and therapies.
